About Cara Therapeutics
Cara Therapeutics is a company based in New York (United States) founded in 2004. Cara Therapeutics has raised $51 million across 5 funding rounds from investors including MVM Partners, Rho Capital Partners and Alta Partners. The company has 79 employees as of December 31, 2022. Cara Therapeutics offers products and services including IPF Therapy and Liver Cancer Treatment. Cara Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter New York, United States
- Employees 79 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$4.33 M (USD)943as on Dec 31, 2024
-
Net Profit
-$70.87 M (USD)40as on Dec 31, 2024
-
EBITDA
-$58.38 M (USD)52as on Dec 31, 2024
-
Total Equity Funding
$51 M (USD)
in 5 rounds
-
Latest Funding Round
$100 K (USD), Post-IPO
Dec 11, 2014
-
Investors
MVM Partners
& 7 more
-
Employee Count
79
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cara Therapeutics
Cara Therapeutics offers a comprehensive portfolio of products and services, including IPF Therapy and Liver Cancer Treatment.
Treatment for idiopathic pulmonary fibrosis through research trials.
Therapy targeting liver cancer in advanced stages.
People of Cara Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Product Management Team
4 people
Finance and Accounting
3 people
Software Development Team
2 people
Data Analysis and Operations Team
2 people
Legal and Compliance
1 people
Human Resources and Administration
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Cara Therapeutics
Cara Therapeutics has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 thousand completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cara Therapeutics
Cara Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MVM Partners, Rho Capital Partners and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech startups are invested in by Rho Capital Partners.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked |
Investor details for Cara Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cara Therapeutics
Investment portfolio details for Cara Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cara Therapeutics
Detailed financials for Cara Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cara Therapeutics Comparisons
Peer comparison for Cara Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cara Therapeutics
Cara Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Cara Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cara Therapeutics
Complete news archive for Cara Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cara Therapeutics
Cara Therapeutics was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Cara Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Christopher Posner is the current CEO of Cara Therapeutics.
Cara Therapeutics is a funded company, having raised a total of $51M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Cara Therapeutics is 79.
Annual revenue of Cara Therapeutics is $4.33M as on Dec 31, 2024.
Cara Therapeutics is developing cannabinoid and opioid receptor targeting therapeutics for pain relief and inflammatory diseases. Its proprietary technology DimerScreen identifies molecular structures that interact with the G-Protein-Coupled Receptors (GPCRS). Its lead candidate, CR845, is a peripheral kappa-opioid receptor agonist and is in Phase III trials for acute postoperative pain and pruritis. The company is also developing cannabinoid receptor agonists for pain relief.
Cara Therapeutics's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
Cara Therapeutics offers IPF Therapy and Liver Cancer Treatment.
Cara Therapeutics has 8 investors. Key investors include MVM Partners, Rho Capital Partners, Alta Partners, Connecticut Innovations, and SWIP.